Drug Enforcement Administration guidance allowing for more flexibility for practitioners to prescribe buprenorphine to new and existing patients with OUD via telephone during the nationwide public health emergency...

OASAS guidance on the Drug Enforcement Administration's recent action of approving buprenorphine induction via telephone amid the COVID-19 pandemic.

Guidance for providers on delivering telepractice services while maintaining patient confidentiality amid the COVID-19 pandemic. Issued 03/23/20.

OASAS is temporarily waiving certain rules and regulations to ensure maximum flexibility and support for certified and/or funded providers. Issued 3/20/20. Updated 3/16/21.

Certified/funded prevention programs are permitted to provide telepractice services (telephonically and/or audiovisually) if a school district or building closes in relation to the COVID-19 emergency.

Guidance outlining an update to the telepractice service waiver to include peer services provided by a Certified Recovery Peer Advocates during the COVID-19 emergency.

This guidance provides clarification on the recently issued telepractice waiver. Issued March 13, 2020.

OASAS is waiving certain regulatory requirements for providing telepractice services amidst the COVID-19 outbreak. Complete and return the attached attestation form to begin providing services.

Complete this attestation and return it to [email protected] and [email protected] to begin providing telepractice services amidst the COVID-19 outbreak.

Consent for the disclosure of communicable diseases including COVID-19 or Novel Coronavirus to the New York State Department of Health. Updated 10/16/20.